Onconetix, Inc. ONCO · Stock Open Onconetix, Inc. in new tab
Onconetix, Inc. Analysis (ONCO)
Is Onconetix, Inc. a good investment? Onconetix, Inc. (ONCO) is currently trading at 0.4068 USD.
In terms of valuation, the stock trades at a P/E ratio of 0.00. This relatively low multiple may signal that Onconetix, Inc. is undervalued compared to historical market norms.
Earnings Schedule: Onconetix, Inc. is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -0.85.
Investor FAQ
Does Onconetix, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Onconetix, Inc.?
Onconetix, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of 285.78.
Company Profile
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.
| Split Date | Split Ratio to 1 |
|---|---|
| Sept. 24, 2024 | 0.03 |
| June 13, 2025 | 1:100 |
| March 25, 2026 | 1:5 |
| May 21, 2026 | 1:10 |
Community Discussion